Teva's Phase 3 study confirms AJOVY's efficacy and safety.

Teva Pharmaceuticals' Phase 3 study confirms AJOVY's efficacy and safety in preventing migraines in adult Chinese patients, reducing monthly migraine days and demonstrating superior efficacy over placebo. AJOVY, a humanized monoclonal antibody, is well-tolerated and has no safety signals observed. The results align with previous Phase 3 data, which led to U.S. and EU approvals in 2018 and 2019, respectively.

April 11, 2024
3 Articles